U. Of Minn. Says Gilead's $20B Hep C Drugs Flout Patent
The University of Minnesota filed a patent infringement suit against Gilead Sciences in Minnesota federal court on Monday alleging the company's blockbuster hepatitis C drugs Sovaldi, Harvoni and Epclusa infringe a...To view the full article, register now.
Already a subscriber? Click here to view full article